Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 616.50
Bid: 617.50
Ask: 618.50
Change: -6.50 (-1.04%)
Spread: 1.00 (0.162%)
Open: 625.00
High: 627.00
Low: 614.00
Prev. Close: 623.00
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

28 Jul 2011 07:00

null

28 July 2011 - Tate & Lyle PLC

Chairman's Annual General Meeting and Interim Management Statement

This Interim Management Statement covers the period from 1 April 2011 to 30 June 2011, which is the first quarter of the financial year. At the Annual General Meeting of Tate & Lyle PLC, to be held in London today, Sir Peter Gershon, Chairman, will make the following statement:

INTERIM MANAGEMENT STATEMENT

OPERATING PERFORMANCE - CONTINUING OPERATIONS

The Group has made an encouraging start to the financial year, with a solid operational performance assisted by strong co-product returns, which were partially offset by the impact of currency movements on the translation of profits.

In our Speciality Food Ingredients division, overall volumes grew over the first quarter of the previous financial year, driven by solid demand for our corn-based speciality sweeteners and SPLENDA® Sucralose. Our plans to re-open the SPLENDA® Sucralose facility in McIntosh, Alabama are proceeding in line with expectations. In Food Systems we saw a continuation of tough trading conditions, particularly in Russia, and expect these to continue for the remainder of the year.

Within Bulk Ingredients, demand for liquid sweeteners remained firm in both the Americas and in Europe. In Europe, as anticipated, starch margins benefited from increased prices for industrial starches, although they were largely offset by sweetener margins which were lower because of higher raw material costs. Citric acid sales were lower than expected in a more competitive market, which we expect to continue for the remainder of the year.

In the first quarter, co-product returns benefited from higher market prices and we locked in sales further forward than usual to take advantage of strong demand. We still anticipate more normal co-product returns for the remainder of the year, especially when compared with the strong co-product performance in the second half of last financial year. Movements in co-products primarily affect the Bulk Ingredients division.

DEBT MANAGEMENT AND BALANCE SHEET

The Group's financial position has continued to strengthen.

Net debt of £454 million at 30 June 2011 has reduced from £464 million at 31 March 2010. The impact of exchange translation on reported net debt in the quarter was negligible. During June, at their maturity, we redeemed the US$300 million bonds from our own funds.

The triennial valuation of the main UK pension scheme as at 31 March 2010 was concluded with a funding deficit of £88 million. Following the sale of the main UK sugar and molasses assets in the last financial year, we will pay £45 million cash into the scheme in the year ending 31 March 2012. The balance of the deficit will be paid at an annual rate of £12 million thereafter.

Following the quarter end, we concluded the refinancing of the Group's US$1 billion revolving credit facility with a new, US$800 million five year committed revolving credit facility.

On July 15, Standard & Poor's upgraded Tate & Lyle's credit rating to "BBB/A-2 (stable outlook)" from "BBB-/A-3 (stable outlook)".

G.C.HAHN & CO

In June, the former owner of G.C. Hahn & Co, which makes up the majority of our Food Systems operations in Europe, exercised their option to sell their remaining 5% shareholding to Tate & Lyle for a total cost of €8 million. As a result, Tate & Lyle now owns 100% of this company.

OUTLOOK

We expect the current demand patterns for our main products in both Speciality Ingredients and Bulk Ingredients to continue. As planned, we are starting to diversify some US grind from Bulk Ingredients to Speciality Food Ingredients. Bulk sweetener volumes in the US are therefore expected to be slightly lower for the full year.

Overall, our expectations for the full year remain unchanged and we continue to anticipate another year of profitable growth.

END

A conference call will be held today at 7:30am BST, hosted by Javed Ahmed, Chief Executive and Tim Lodge, Chief Financial Officer. Participants are requested to dial in at least 5 minutes before the commencement of the call. Dial in details are as follows:

Participant dial in number: +44 (0) 1452 555 566Conference ID: 83482849Replay dial in number: +44 (0) 1452 55 00 00Replay passcode: 83482849#

A replay of this call will be available from two hours after the end of the live call for 7 days until 3 August 2011.

For more information contact Tate & Lyle PLC:

Mathew Wootton, Group VP, Investor and Media RelationsTel: +44 (0) 20 7977 6211 or Mobile: +44 (0) 7500 100 320

Andrew Lorenz (Financial Dynamics), Media RelationsTel: +44 (0) 20 7269 7113 or Mobile: +44 (0) 7775 641 807

Copyright Business Wire 2011

Date   Source Headline
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company
10th Aug 20234:00 pmRNSHolding(s) in Company
7th Aug 202312:15 pmRNSDirector/PDMR Shareholding
3rd Aug 20233:45 pmRNSDirector/PDMR Shareholding
2nd Aug 202311:30 amRNSHolding(s) in Company
1st Aug 202311:15 amRNSTotal Voting Rights
28th Jul 202312:00 pmRNSDirector/PDMR Shareholding
27th Jul 20231:15 pmRNSResult of AGM
27th Jul 20239:30 amRNSHolding(s) in Company
26th Jul 202311:30 amRNSHolding(s) in Company
25th Jul 202311:30 amRNSHolding(s) in Company
24th Jul 202312:30 pmRNSHolding(s) in Company
18th Jul 202312:30 pmRNSHolding(s) in Company
4th Jul 20233:00 pmRNSDirector/PDMR Shareholding
3rd Jul 20232:10 pmRNSBlock listing Interim Review
3rd Jul 20232:00 pmRNSTotal Voting Rights
3rd Jul 20237:02 amRNSDirectorate Change
29th Jun 20233:30 pmRNSHolding(s) in Company
28th Jun 20232:00 pmRNSHolding(s) in Company
7th Jun 20232:30 pmRNSDirector/PDMR Shareholding
6th Jun 202312:30 pmRNSAnnual Financial Report and Notice of AGM 2023
1st Jun 202312:00 pmRNSTotal Voting Rights
25th May 20237:00 amRNSFinal Results
18th May 20239:30 amRNSDirector Declaration
2nd May 20232:30 pmRNSTotal Voting Rights
4th Apr 202311:00 amRNSOperating Segment Restatement
3rd Apr 20234:15 pmRNSTotal Voting Rights
8th Mar 20232:30 pmRNSDirector/PDMR Shareholding
8th Feb 20237:00 amRNSCapital Markets Event
26th Jan 20237:00 amRNSTrading Statement
6th Jan 20232:00 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:17 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.